This CHMP position statement replaces the CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products (EMA/CHMP/BWP/303353/2010).

Keywords: Creutzfeldt-Jakob disease, human transmissible spongiform encephalopathies, plasma-derived medicinal products, urine-derived medicinal products, sporadic CJD, genetic CJD, iatrogenic CJD, variant CJD, blood infectivity, transmissibility

Current version

CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - Revision 3

Document history - Revision 2

CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - Revision 2

Overview of comments received on 'Committee for Medicinal Products for Human Use position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products'

Draft CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - Revision 2

Document history - Revision 1

Concept paper on the need to update the CHMP position statement on CJD and plasma-derived and urine-derived medicinal products (EMEA/CPMP/BWP/2879/02 REV. 1)

CHMP position statement on Creutzfeldt-Jacob disease and plasma-derived and urine-derived medicinal products - Revision 1

Document history - First version

CPMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products - First version

CPMP position statement on new variant CJD and plasma-derived medicinal products - Superseded by CPMP/BWP/2879/02

How useful do you find this page?